Cantor Fitzgerald Estimates GH Research FY2024 Earnings

GH Research PLC (NASDAQ:GHRS) – Stock analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for GH Research in a note issued to investors on Thursday, February 13th. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings of ($0.79) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $14.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. Cantor Fitzgerald also issued estimates for GH Research’s FY2025 earnings at ($0.80) EPS.

A number of other research analysts have also recently weighed in on GHRS. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Monday, January 27th. Canaccord Genuity Group dropped their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th.

GH Research Stock Down 2.1 %

GHRS opened at $14.01 on Monday. The stock has a market cap of $728.94 million, a price-to-earnings ratio of -17.73 and a beta of 0.93. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50. The company’s 50-day moving average price is $9.83 and its two-hundred day moving average price is $9.10.

Institutional Trading of GH Research

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP increased its holdings in GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after acquiring an additional 41,711 shares during the period. Two Sigma Investments LP bought a new stake in GH Research during the 4th quarter worth approximately $117,000. Millennium Management LLC bought a new position in shares of GH Research in the 4th quarter worth $145,000. BNP Paribas Financial Markets bought a new position in shares of GH Research in the 4th quarter worth $44,000. Finally, AdvisorShares Investments LLC increased its holdings in shares of GH Research by 15.4% in the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock worth $252,000 after buying an additional 4,806 shares during the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).